Praluent 150 mg/mL (Alirocumab INJECTION, SOLUTION) 150 mg/mL

Praluent 150 mg/mL is a lipid-lowering agent used to manage cholesterol levels in specific conditions. It is indicated for patients who require additional lowering of LDL-cholesterol.

• Heterozygous familial hypercholesterolemia: Reduces LDL-cholesterol levels in patients with this genetic condition.
• Homozygous familial hypercholesterolemia: Helps manage cholesterol levels in patients with this more severe inherited condition.
• Primary hyperlipidemia: Lowers LDL-cholesterol in patients with primary hyperlipidemia.
• Mixed dyslipidemia: Manages cholesterol levels in patients with mixed dyslipidemia.

• Praluent 150 mg/mL works by binding and inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove LDL-cholesterol from the blood. By inhibiting PCSK9, Praluent increases the number of LDL receptors on the liver's surface, which enhances the liver's ability to clear LDL-cholesterol from the bloodstream, thereby lowering LDL-cholesterol levels.

Praluent 150 mg/mL may cause side effects, although not everyone experiences them. Common Side Effects:

• Injection site reactions: Redness, swelling, or itching at the injection site.
• Nasopharyngitis: Common cold symptoms.
• Upper respiratory tract infection: Symptoms such as a runny or stuffy nose, sneezing, and sore throat.
• Flu-like symptoms: General discomfort, fever, and fatigue.
• Back pain: Discomfort or pain in the back.
• Serious or Rare Side Effects:
• Hypersensitivity reactions: Severe allergic reactions, including anaphylaxis.
• Immune-mediated conditions: Development of autoimmune conditions.
• Liver problems: Elevated liver enzymes or liver dysfunction.
• Neurological symptoms: Memory problems or confusion.

Praluent 150 mg/mL should be used with caution in certain situations. Consult your healthcare provider for personalized advice.

• Allergic reactions: Inform your doctor if you have a history of allergic reactions to alirocumab or any of its components.
• Liver disease: Use with caution in patients with liver disease, as it may affect liver function.
• Pregnancy: The safety of Praluent during pregnancy has not been established. Consult your doctor if you are pregnant or planning to become pregnant.
• Breastfeeding: It is not known whether alirocumab passes into breast milk. Consult your doctor if you are breastfeeding.
• Children: Safety and effectiveness in pediatric patients have not been established.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Praluent 150 mg/mL may interact with other medications, potentially affecting its efficacy or increasing the risk of side effects. Major Interactions (Avoid):

• None identified.

Moderate Interactions (Monitor Closely)

• Other lipid-lowering drugs: Concurrent use with other lipid-lowering drugs may increase the risk of side effects.
• Immunosuppressants: May increase the risk of infections.
• Corticosteroids: May increase the risk of immune-mediated conditions.
• Anticoagulants: May increase the risk of bleeding.
• Antiplatelet drugs: May increase the risk of bleeding.